Efficacy, tolerability, and pharmacokinetics of oxcarbazepine oral loading in patients with epilepsy

Epilepsia

Volumn 53, Issue 1, 2012, Pages

  Kim, Dong Wook ^a   Gu, Nami ^b   Jang, In Jin ^b   Chu, Kon ^c   Yu, Kyung Sang ^b   Cho, Joo Youn ^b   Yoon, Seo Hyun ^b   Kim, Hwa Suk ^b   Oh, Jeeyoung ^a   Lee, Sang Kun ^c  

^a Konkuk University School of Medicine   (South Korea)

^b Seoul National University   (South Korea)

^c Seoul National University Hospital   (South Korea)

Author keywords

Oral loading; Oxcarbazepine; Pharmacokinetics

Indexed keywords

10,11 DIHYDRO 10 HYDROXYCARBAZEPINE; DIBENZAZEPINE DERIVATIVE; DRUG METABOLITE; OXCARBAZEPINE; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ALLERGIC REACTION; AREA UNDER THE CURVE; ARTICLE; ATAXIA; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL TRIAL; DIPLOPIA; DISEASE SEVERITY; DIZZINESS; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ELIMINATION; DRUG ERUPTION; DRUG HALF LIFE; DRUG TOLERABILITY; DRUG WITHDRAWAL; ELECTROENCEPHALOGRAPHY; EPILEPSY; FEMALE; HUMAN; LOADING DRUG DOSE; MACULOPAPULAR RASH; MALE; NAUSEA AND VOMITING; NEUROLOGIC DISEASE; NYSTAGMUS; PATIENT COMPLIANCE; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PRURITUS; RECURRENT DISEASE; SINGLE DRUG DOSE;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; ANTICONVULSANTS; CARBAMAZEPINE; EPILEPSY; FEMALE; HUMANS; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84855469931     PISSN: 00139580     EISSN: 15281167     Source Type: Journal    
DOI: 10.1111/j.1528-1167.2011.03318.x     Document Type: Article

References (13)

1. Arif H, Buchsbaum R, Weintraub D, Koyfman S, Salas-Humara C, Bazil CW, Resor SR Jr, Hirsch LJ,. (2007) Comparison and predictors of rash associated with 15 antiepileptic drugs. Neurology 68: 1701-1709. (Pubitemid 46763258)
2. Buggy Y, Layton D, Fogg C, Shakir SA,. (2010) Safety profile of oxcarbazepine: results from a prescription-event monitoring study. Epilepsia 51: 818-829.
3. Cramer JA, Mintzer S, Wheless J, Mattson RH,. (2010) Adverse effects of antiepileptic drugs: a brief overview of important issues. Expert Rev Neurother 10: 885-891.
4. Dam M, Ekberg R, Loyning Y, Waltimo O, Jakobsen K,. (1989) A double-blind study comparing oxcarbazepine and carbamazepine in patients with newly diagnosed, previously untreated epilepsy. Epilepsy Res 3: 70-76. (Pubitemid 19009372)
5. Dong X, Leppik IE, White J, Rarick J,. (2005) Hyponatremia from oxcarbazepine and carbamazepine. Neurology 65: 1976-1978. (Pubitemid 43970125)
6. Ferrendelli JA,. (2001) Concerns with antiepileptic drug initiation: safety, tolerability, and efficacy. Epilepsia 42 (Suppl. 4): 28-30. (Pubitemid 32802084)
7. Hung SI, Chung WH, Liu ZS, Chen CH, Hsih MS, Hui RC, Chu CY, Chen YT,. (2010) Common risk allele in aromatic antiepileptic-drug induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Han chinese. Pharmacogenomics 11: 349-356.
8. Johannessen SI, Battino D, Berry DJ, Bialer M, Kramer G, Tomson T, Patsalos PN,. (2003) Therapeutic drug monitoring of the newer antiepileptic drugs. Ther Drug Monit 25: 347-363. (Pubitemid 36638181)
9. Kim BK, Bae HJ, Jang IJ, Park SH, Lee SK,. (2000) The serum levels and side effects of single oral loading of controlled-release carbamazepine. J Korean Neurol Assoc 18: 276-280.
10. Park SP, Kwon SH,. (2008) Cognitive effects of antiepileptic drugs. J Clin Neurol 4: 99-106.
11. Schmidt D, Elger CE,. (2004) What is the evidence that oxcarbazepine and carbamazepine are distinctly different antiepileptic drugs? Epilepsy Behav 5: 627-635. (Pubitemid 40392577)
12. Van Der Meyden CH, Kruger AJ, Muller FO, Rabie W, Schall R,. (1994) Acute oral loading of carbamazepine-CR and phenytoin in a double-blind randomized study of patients at risk of seizures. Epilepsia 35: 189-194. (Pubitemid 24074485)
13. van Opstal JM, Janknegt R, Cilissen J, L'Ortije WH, Nel JE, De Heer F,. (2004) Severe overdosage with the antiepileptic drug oxcarbazepine. Br J Clin Pharmacol 58: 329-331. (Pubitemid 39209067)